GlaxoSmithKline (now GSK plc) is a British multinational pharmaceutical and biotechnology company formed through the merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London and operates globally.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
The FDA reversed its refusal to review Moderna's mRNA flu vaccine application after the company amended its submission. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision expected by August 5, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780669 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780656 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780643 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780305 |
Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria |
NOT_YET_RECRUITING | |
| NCT07748689 |
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07747480 |
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07747467 |
A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07742644 |
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age |
NOT_YET_RECRUITING | PHASE3 |
| NCT07742527 |
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care |
NOT_YET_RECRUITING | PHASE1 |
| NCT07740720 |
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE3 |
